Research ArticleCancer

Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape

See allHide authors and affiliations

Science Translational Medicine  25 Mar 2020:
Vol. 12, Issue 536, eaay8456
DOI: 10.1126/scitranslmed.aay8456

Article Information

vol. 12 no. 536

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication July 23, 2019
  • Resubmitted December 17, 2019
  • Accepted for publication March 3, 2020
  • .

Author Information

  1. Constance J. Martin1,*,
  2. Abhishek Datta1,*,
  3. Christopher Littlefield1,
  4. Ashish Kalra1,
  5. Christopher Chapron1,
  6. Stefan Wawersik1,
  7. Kevin B. Dagbay1,
  8. Christopher T. Brueckner1,
  9. Anastasia Nikiforov1,
  10. Francis T. Danehy Jr.1,
  11. Frederick C. Streich Jr.1,
  12. Christopher Boston1,
  13. Allison Simpson1,,
  14. Justin W. Jackson1,
  15. Susan Lin1,
  16. Nicole Danek1,
  17. Ryan R. Faucette1,
  18. Pichai Raman2,,
  19. Allan D. Capili1,§,
  20. Alan Buckler1,
  21. Gregory J. Carven1 and
  22. Thomas Schürpf1,||
  1. 1Scholar Rock, Inc., Cambridge, MA 02139, USA.
  2. 2Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
  1. ||Corresponding author. Email: thomas{at}scholarrock.com
  • * These authors contributed equally to this work.

  • Present address: Cellarity, Cambridge, MA 02142, USA.

  • Present address: GSK, Collegeville, PA 19426, USA.

  • § Present address: Amagma Therapeutics, Waltham, MA 02453, USA.

Altmetric

Article usage

Article usage: March 2020 to July 2020

AbstractFullPdf
Mar 202059251107915
Apr 20201588581523
May 20201002282243
Jun 2020185342219
Jul 202053015

Stay Connected to Science Translational Medicine

Navigate This Article